AMGN Q3 2026 deep dive: robust product sales and pipeline advances drive guidance increase

What happened

Amgen reported third-quarter 2026 revenue of $10.37 billion, up 8.5% from a year earlier and above analysts’ estimates. Adjusted profit was $6.45 per share, also above estimates. The company raised its full-year revenue guidance midpoint to $39.3 billion and adjusted profit guidance midpoint to $23.30 per share.

Confirmed

Global impact / market context

Higher sales and profit, alongside raised full-year guidance, indicate that Amgen expects stronger results than it previously forecast. If the sales momentum continues, it could support revenue and cash available for research, development, and other spending; weaker product demand could make the higher outlook harder to achieve.

Analyst inference

The article reports results above analyst estimates and guidance increases, but provides no share-price reaction or comparison with other drugmakers. For investors, the key distinction is between a strong reported quarter and whether future product sales sustain the company’s higher full-year expectations.

Analyst inference

What to watch

1. Watch whether Amgen’s subsequent reports show revenue tracking toward the $39.3 billion full-year midpoint; that would test whether the raised outlook is being delivered. Analyst inference
2. Track adjusted profit against the $23.30-per-share full-year midpoint, since rising costs could limit how much stronger sales translate into profit. Analyst inference
3. The article attributes strength to six core products and says 17 products annualize above $1 billion; it gives no product-level sales breakdown. Confirmed

Evidence

• stockstory.org